AMED Price Prediction Next Week
Analysis and Insights
News Sentiment and Earnings Report:
Amedisys (AMED) reported Q4 revenue of $598.1 million, missing the consensus estimate of $602.38 million. The Q4 adjusted EPS of $0.96 also fell short of the expected $1.06, reflecting cost pressures and mixed performance. Additionally, the merger with UnitedHealth (UNH) faces uncertainty due to a DOJ lawsuit, with a trial scheduled for October 27, 2025, or later. Both companies have waived their right to terminate the agreement, adding to the merger's unpredictability.
Technical Indicators:
- RSI (14-period): 52.86, indicating a neutral position, not overbought or oversold.
- MACD: 0.22, showing a weak bullish signal.
- Bollinger Bands: The stock is trading near the middle of the bands, with a BBP of 0.58, suggesting moderate volatility.
- Fibonacci Levels: Pivot at 92.29, with resistance levels at 92.97 and 93.38, and support at 91.61.
Price Prediction:
Given the current technical indicators and the uncertain news surrounding the merger, AMED is expected to trade with caution. The stock may face resistance at 93.38, but if it breaks above, it could target 94.06. Conversely, failure to breach resistance may lead to a drop to 91.61.
Recommendation:
Buy AMED with a target price of $94.1 for the next trading week. Monitor the stock's movement relative to the Fibonacci resistance levels and merger-related news for potential adjustments.
AMED Similar Chart Price Prediction
The price of AMED is predicted to go up 1.12%, based on the high correlation periods with TBRG. The similarity of these two price pattern on the periods is 93.22%.
AMED
TBRG
Up: 1.12%Similarity: 93.22%
